Long-Term Castration-Related Outcomes In Patients With High-Risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With Or Without Docetaxel And Estramustine In The Unicancer Getug-12 Trial
CLINICAL GENITOURINARY CANCER(2020)
摘要
Addition of taxane-based chemotherapy to androgen deprivation therapy improved relapse-free survival in men with high-risk localized prostate cancer; however, long-term toxicities are unknown. This longitudinal study of 78 patients from the GETUG-12 randomized trial treated at Gustave Roussy shows that additional chemotherapy with docetaxel and estramustine does not impact the restoration of androgen secretion and related side effects after castration discontinuation.Introduction: Neoadjuvant chemotherapy with docetaxel and estramustine (DE) significantly improved relapse-free survival in patients with high-risk localized prostate cancer treated with androgen deprivation therapy (ADT) for 3 years and a local treatment in the GETUG-12 phase III trial. We sought to explore whether the addition of DE impacts long-term treatment-related side effects. Patients and Methods: Patients randomized within the UNICANCER GETUG-12 trial at Gustave Roussy who were alive when ADT was discontinued were followed-up prospectively. Serum testosterone levels and clinical data regarding body weight, libido, erection, and cardio-vascular events were collected. Results: Seventy-eight patients were included: 36 patients had been treated with ADT plus a local treatment and 42 with ADTthornDE plus a local treatment. With a median follow-up of 5.9 years after ADT discontinuation, serum testosterone levels returned to normal values (>= 200 ng/mL) for 57 (78%) of 72 evaluable patients, and 29 (43%) of 68 evaluable patients reported erections allowing intercourse without medical assistance. No impact of DE on testosterone level recovery, libido, quality of erections, and changes in body weight after ADT discontinuation was detected. The incidence of cardiovascular events was low and similar in both treatment arms. Conclusion: Treatment with DE was not associated with excess long-term castration-related toxicity in men with high-risk localized prostate cancer. The relapse-free survival improvement seen with DE in GETUG-12 is likely not related to differed testosterone recovery. (C) 2020 Elsevier Inc. All rights reserved.
更多查看译文
关键词
Cardiovascular events, Erectile dysfunction, Libido, Neoadjuvant chemotherapy, Testosterone
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络